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Assembly of an A kinase-anchoring protein–β2-adrenergic receptor
complex facilitates receptor phosphorylation and signaling
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Robert J. Lefkowitz† and John D. Scott*
Phosphorylation of G-protein-coupled receptors by
second-messenger-stimulated kinases is central to the
process of receptor desensitization [1–3].
Phosphorylation of the β2-adrenergic receptor (β2-AR)
by protein kinase A (PKA), in addition to uncoupling
adenylate cyclase activation, is obligatory for receptor-
mediated activation of mitogen-activated protein
kinase (MAP kinase) cascades [4,5]. Although
mechanisms for linking G-protein-coupled receptor
kinases to the activated receptor are well established,
analogous mechanisms for targeting second
messenger kinases to the β2-AR at the plasma
membrane have not been elucidated. Here we show
that the A-kinase-anchoring protein, AKAP79/150,
co-precipitates with the β2-AR in cell and tissue
extracts, nucleating a signaling complex that includes
PKA, protein kinase C (PKC) and protein phosphatase
PP2B. The anchoring protein directly and constitutively
interacts with the β2-AR and promotes receptor
phosphorylation following agonist stimulation.
Functional studies show that PKA anchoring is required
to enhance β2-AR phosphorylation and to facilitate
downstream activation of the MAP kinase pathway. This
defines a role for AKAP79/150 in the recruitment of
second-messenger-regulated signaling enzymes to a
G-protein-coupled receptor. 
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Results and discussion
To determine if kinase signaling complexes interact with
G-protein-coupled receptors, a detergent (CHAPS)-solubi-
lized rat brain lysate was immunoprecipitated with an anti-
body specific for β2-AR. Immunoprecipitates were analyzed
for co-purifying A-kinase anchoring proteins (AKAPs) by an
in vitro overlay procedure using radiolabeled PKA regulatory
subunit (RII) as a probe [6]. Several RII-binding proteins
were detected in the brain extract upon longer exposure but
only the predominant RII-binding protein of approximately
150 kDa co-precipitated with the β2-AR (Figure 1a). The
RII-binding protein was identified as AKAP150 (the rat
homolog of human AKAP79) by immunoblotting
(Figure 1b). The band at approximately 55 kDa that co-pre-
cipitated with AKAP150 is RII and was detected by dimer-
ization with the labeled RII probe (Figure 1a). Reciprocal
experiments detected β2-AR upon immunoprecipitation of
AKAP150 from brain lysates (Figure 1c). 
The AKAP79/150 family of anchoring proteins (comprising
human AKAP79, rat/mouse AKAP150 and bovine AKAP75)
Figure 1
Identification of a β2-AR–AKAP150 complex in rat brain by co-
immunoprecipitation. (a) RII-binding proteins identified by overlay
assay [6] in β2-AR immunoprecipitate. (b) The major RII-binding band
co-purifying with the β2-AR is identified as AKAP150 by
immunoblotting with specific antibody . (c) β2-AR detected by
immunoblot in AKAP150 immunoprecipitate. (d–f) Immunoblot
detection of signaling enzymes. (d) PKA, (e) PP2B and (f) PKC in
β2-AR immunoprecipitates from rat brain extract. Blots are
representative of at least three separate experiments. Ex, source extract
((a,b) 2 µg; (c–f) 20 µg); Pi, control pre-immune sera precipitation; IP,
specific immunoprecipitation; IB, immunoblot. Complete experimental
methods are given in the Supplementary material.
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has been shown to maintain a multi-enzyme signaling scaf-
fold that includes the kinases PKA and PKC and the
protein phosphatase PP2B [7,8]. Both kinases have a role in
the control of β2-AR function [2], and there is evidence for
PP2B activity associated with the receptor [9]. All three sig-
naling enzymes were detected by immunoblot when β2-AR
immunoprecipitates were analyzed with specific antibodies
(Figure 1d–f). These data show that the AKAP150 protein
maintains a signaling complex of three second-messenger-
regulated enzymes with β2-AR inside cells.
To investigate the functional consequences of the inter-
action between this AKAP and β2-AR in a heterologous
expression system, HEK293 cells were transfected with
cDNAs for AKAP79 and for β2-AR tagged with a Flag
epitope. Despite the difference in size, AKAP79 and
AKAP150 are highly conserved. An extended repeat
sequence of unknown function accounts for the higher
molecular weight of AKAP150. As expected, recombinant
AKAP79 and endogenous PKA co-precipitated with the
β2-AR (Figure 2a,b). Most interactions of β2-AR with other
proteins occur transiently at particular stages of receptor
activation and desensitization [3,10,11]. Several other sig-
naling partners such as heterotrimeric G proteins, receptor
kinases, arrestins and tyrosine kinases bind to β2-AR in an
agonist-dependent manner [3,10,11]. Thus, serum-starved
HEK293 cells transfected with AKAP79 and β2-AR were
stimulated with the β2-AR agonist isoproterenol to deter-
mine whether complex formation was dependent on the
receptor being occupied. There was no difference in the
levels of AKAP or PKA catalytic subunit that co-immuno-
precipitated with β2-AR in the absence or presence of iso-
proterenol (n = 9; Figure 2c). This indicates a constitutive
association of β2-AR with AKAP79/150 in the signaling
complex. A stable β2-AR–AKAP79/150 complex would be
consistent with the maintenance of a signaling scaffold
that integrates second-messenger-mediated signals. 
Most regulatory phosphorylation sites and binding sites for
β2-AR-interacting proteins are contained within the third
intracellular loop (i3) and the carboxy-terminal tail (ct) of
the receptor [11,12]. Consequently, glutathione-S-trans-
ferase (GST) fusions with the i3 and ct domains were used
as probes to investigate the β2-AR–AKAP79/150 interac-
tion. In GST pulldowns from rat brain extracts, endoge-
nous AKAP150 interacted with both GST–i3 and GST–ct
but not with a control GST construct (Figure 2d). Similar
results were obtained using purified recombinant AKAP79
and the same GST–receptor fragments in vitro, indicating
that association of AKAP79 with β2-AR was a result of a
direct interaction between the two proteins (Figure 2e).
Thus, AKAP79/150 binds through two sites on the β2-AR,
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Figure 2
Characterization of the β2-AR–AKAP79
interaction. (a) AKAP79 and (b) PKA co-
precipitate with Flag–β2-AR from transfected
HEK293 cells. (c) The β2-AR–AKAP79
interaction is not agonist dependent. AKAP79
and PKA co-immunoprecipitated with β2-AR
from HEK293 cells at specific time points
(indicated above each lane) after application
of the agonist isoproterenol (10 µM) are
shown. (d,e) GST fusion proteins including
the i3 (residues 222–270) and ct (residues
328–413) β2-AR domains were used in
pulldown assays. (d) AKAP150 immunoblot of
eluates from glutathione–Sepharose resins
incubated with rat brain extract. (e) AKAP79
immunoblot of eluates from glutathione–
Sepharose resins incubated with purified
AKAP79 protein. (f) RII-binding proteins
identified by overlay assay in
immunoprecipitates of specific receptors from
HEK293 cells transfected with β2-AR,
α2A-AR, angiotensin 1A receptor (AT1A-R) or
VIP receptor (VIP-R). AKAP79 specifically
co-precipitates only with β2-AR. Blots are
representative of at least four separate
experiments. Ex, source extract (a,b,f) 20 µg;
(d) 2 µg, (e) 0.1 µg pure AKAP79 protein; Pi,
control pre-immune sera precipitation; IP,
specific immunoprecipitation; IB, immunoblot.
Complete experimental methods are given in
the Supplementary material.
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which may explain the constitutive nature of the interac-
tion (Figure 2c). To investigate the specificity of the
AKAP79/150 interaction with G-protein- coupled recep-
tors, HEK293 cells were transfected with epitope-tagged
expression plasmids for β2-AR, α2A-adrenergic receptor
(α2A-AR), angiotensin 1A receptor (AT1A-R) or vasoactive
intestinal polypeptide receptor (VIP-R). AKAP79 only co-
precipitated with β2-AR, suggesting selectivity for β2-AR
over other prototypic examples of transmembrane recep-
tors coupled to Gs, Gi or Gq. 
Many metabolic effects that follow agonist stimulation of
the β2-AR are propagated by Gs-mediated stimulation of
adenylate cyclase, production of cAMP and subsequent
activation of PKA [13]. PKA phosphorylation of the
β2-AR mediates a negative feedback through uncoupling
of the receptor–Gs interaction [1]. We postulated that aβ2-AR–AKAP79/150 complex would function to enhance
cAMP-dependent phosphorylation by bringing the kinase
into close proximity to the receptor. Therefore, agonist-
dependent phosphorylation of β2-AR was measured in
HEK293 cells transfected with Flag-tagged β2-AR in the
absence and presence of various AKAP79 proteins
(Figure 3a). A 46 ± 10% (n = 4) increase in receptor phos-
phorylation was measured in cells expressing wild-type
AKAP79 (Figure 3a). In contrast, cells transfected with
the AKAP79-Pro mutant, which is unable to bind PKA
[14,15], exhibited a 54 ± 14% (n = 4) decrease in β2-AR
phosphorylation (Figure 3a). Thus the AKAP79-Pro
mutant may exert a dominant-negative effect by compet-
ing with the low levels of endogenous AKAP79 in
HEK293 cells [16,17] for association with the β2-AR. A
more pronounced decrease in receptor phosphorylation
(65 ± 15% (n = 4)) was observed upon co-expression of
the truncated AKAP79108–427 (Figure 3a). This AKAP79
fragment retains full PKA-binding activity but is unable
to interact with the receptor (data not shown), thereby
displacing the β2-AR-associated pool of PKA holoenzyme.
Additional controls confirmed that changes in the phos-
phorylation state of β2-AR were mediated by anchored
pools of PKA. The PKA-anchoring inhibitor Ht31, which
contains the helical PKA-binding determinant conserved
in AKAP proteins, has previously been used to uncouple
anchored PKA from several substrates [18–20].
Co-expression of Ht31 caused a 52 ± 12% (n = 3) decrease
in β2-AR phosphorylation whereas expression of a control
reagent that does not bind PKA (Ht31-Pro) had no effect
(Figure 3b). Similarly, receptor phosphorylation was
decreased by 65 ± 10% (n = 3) when the specific PKA
inhibitor PKI was co-expressed with the β2-AR (Figure
3c). Collectively, these results indicate that a functional
consequence of AKAP79 targeting is facilitation of cAMP-
dependent phosphorylation of β2-AR by an anchored pool
of PKA holoenzyme. 
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Figure 3
Effects of PKA anchoring on β2-AR
phosphorylation and activation of MAP kinase.
(a) Agonist-stimulated β2-AR phosphorylation
is increased in cells overexpressing AKAP79
but is significantly inhibited by AKAP79-Pro
and AKAP79108–427 mutants. HEK293 cells
were subsequently stimulated with 10 µM
isoproterenol for 5 min. A representative gel
shows basal (–) and isoproterenol-stimulated
(+) phosphorylation of β2-AR  in cells
transfected as indicated. Values are normalized
with respect to receptor expression levels using
FACS analysis and are expressed relative to
isoprotenerol-stimulated β2-AR phosphorylation
in the absence of co-transfected AKAP79
(Control). (b) Disruption of PKA anchoring by
Ht31 inhibits agonist-stimulated β2-AR
phosphorylation. (c) Agonist-stimulated β2-AR
phosphorylation is inhibited by the PKA
inhibitor PKI. (d) Recruitment of PKA to the
plasma membrane is required for β2-AR-
regulated Erk1 activation. β2-AR and HA–Erk1
were expressed in HEK293 cells with pcDNA3
(Control), PKI, Ht31 or Ht31-Pro. Cells starved
of serum overnight were stimulated with 10 µM
isoproterenol for 5 min at 37°C before
determination of Erk activity. Values represent
means ± SEM of three to seven independent
experiments. Complete experimental methods
are given in the Supplementary material.
bb10g55.qxd  04/03/2000  01:19  Page 411
PKA phosphorylation of the β2-AR induces a switch in
G-protein coupling from Gs to Gi [4,5,21], which promotes a
receptor-regulated mitogenic signaling cascade mediated
by Gi, β-arrestin and the tyrosine kinase Src [22]. We there-
fore investigated the effect of PKA anchoring on agonist-
dependent activation of the MAP kinase cascade in
HEK293 cells transiently expressing a hemagglutinin (HA)-
tagged MAP kinase, Erk1. MAP kinase activity was
increased by 43 ± 13% (n = 7) in response to isoproterenol
and, consistent with previous observations [4], activity was
decreased 31 ± 17% (n = 4) by co-expression of the PKA-
specific inhibitor PKI (Figure 3d). Overexpression of the
PKA-anchoring inhibitor Ht31 decreased MAP kinase activ-
ity by 21 ± 3% (n = 7), whereas the Ht31-Pro control reagent
had no inhibitory effect (Figure 3d). This implies that dis-
placement of PKA from AKAP79 impairs the transduction
of signals downstream from β2-AR. Interestingly, a recent
study suggested a role for the cytoskeletal anchoring
protein gravin in β2-AR resensitization [10]. There is,
however, no evidence for plasma membrane localization of
gravin, a predominantly soluble protein in most cell types
[23,24], and gravin does not co-precipitate with β2-AR in
brain extracts (Figure 1a). Furthermore, we did not find evi-
dence for in vitro interaction between gravin and the i3 and
the ct receptor domains. These findings do not, however,
preclude the possibility that gravin could be coupled to the
internalized β2-AR through an adaptor protein.
In conclusion, our data suggest a central role for
AKAP79/150 in mediating the localization of signaling
enzymes to the β2-AR at the plasma membrane. They also
emphasize that PKA anchoring contributes to effective
β2-AR-mediated mitogenic signaling. We also show that
AKAP79/150 exists in a complex with the β2-AR in vivo and
regulates the phosphorylation state of the receptor. Given
that the β2-AR is the prototypic member of an extensive
G-protein-coupled receptor family, these findings may
have wider implications. Recruitment of second-messen-
ger-regulated signaling enzymes by scaffolding proteins
such as AKAP79/150 may prove to be a conserved mecha-
nism in the regulation of G-protein-coupled receptors.
Supplementary material
Supplementary material including complete experimental methods is
available at http://current-biology.com/supmat/supmatin.htm.
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